Fig. 6

CXCR1+ neutrophils mediate resistance to Third-Generation EGFR TKIs. a Relative survival curve describing the viability of indicated H1975 treated with the indicated concentrations of osimertinib. b Relative survival curve describing the viability of indicated PC-9 treated with the indicated concentrations of osimertinib. c Growth curves of xenograft tumors derived from H1975_OR following osimertinib treatment or in combination with reparixin. d Growth curves of xenograft tumors derived from PC-9_OR following osimertinib treatment or in combination with reparixin. e Body weight changes during experiment in H1975_OR mouse models. f Body weight changes during experiment in PC-9_OR mouse models. g Flow cytometry of CXCR1+ neutrophil proportion in H1975_OR mouse models. h Flow cytometry of CXCR1+ neutrophil proportion in PC-9_OR mouse models. i Represent images of intravital tumor imaging with CXCR1+ neutrophils by DAOSLIMIT in the H1975_OR and PC-9_OR mouse models. OR, osimertinib resistance